KR100988451B1 - TNFR-Ig 융합 단백질의 제조 - Google Patents

TNFR-Ig 융합 단백질의 제조 Download PDF

Info

Publication number
KR100988451B1
KR100988451B1 KR1020077004810A KR20077004810A KR100988451B1 KR 100988451 B1 KR100988451 B1 KR 100988451B1 KR 1020077004810 A KR1020077004810 A KR 1020077004810A KR 20077004810 A KR20077004810 A KR 20077004810A KR 100988451 B1 KR100988451 B1 KR 100988451B1
Authority
KR
South Korea
Prior art keywords
culture
glutamine
medium
culture conditions
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077004810A
Other languages
English (en)
Korean (ko)
Other versions
KR20070069140A (ko
Inventor
데니스 드라포
옌-퉁 루안
제임스 알 머서
웬지 왕
다니엘 알 라스코
Original Assignee
와이어쓰 리서치 아일랜드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35500648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100988451(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 와이어쓰 리서치 아일랜드 리미티드 filed Critical 와이어쓰 리서치 아일랜드 리미티드
Publication of KR20070069140A publication Critical patent/KR20070069140A/ko
Application granted granted Critical
Publication of KR100988451B1 publication Critical patent/KR100988451B1/ko
Assigned to 화이자 아일랜드 파마슈티칼즈 reassignment 화이자 아일랜드 파마슈티칼즈 권리의 전부이전등록 Assignors: 와이어쓰 리서치 아일랜드 리미티드
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077004810A 2004-08-27 2005-08-26 TNFR-Ig 융합 단백질의 제조 Expired - Lifetime KR100988451B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60537904P 2004-08-27 2004-08-27
US60/605,379 2004-08-27

Publications (2)

Publication Number Publication Date
KR20070069140A KR20070069140A (ko) 2007-07-02
KR100988451B1 true KR100988451B1 (ko) 2010-10-18

Family

ID=35500648

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077004810A Expired - Lifetime KR100988451B1 (ko) 2004-08-27 2005-08-26 TNFR-Ig 융합 단백질의 제조

Country Status (37)

Country Link
US (1) US7300773B2 (cg-RX-API-DMAC7.html)
EP (2) EP1781802B1 (cg-RX-API-DMAC7.html)
JP (3) JP2008511330A (cg-RX-API-DMAC7.html)
KR (1) KR100988451B1 (cg-RX-API-DMAC7.html)
CN (2) CN102876761A (cg-RX-API-DMAC7.html)
AR (2) AR050537A1 (cg-RX-API-DMAC7.html)
AT (2) ATE461285T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005280036B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0514694B8 (cg-RX-API-DMAC7.html)
CA (1) CA2578138C (cg-RX-API-DMAC7.html)
CL (1) CL2017000577A1 (cg-RX-API-DMAC7.html)
CR (2) CR8998A (cg-RX-API-DMAC7.html)
CY (2) CY1109721T1 (cg-RX-API-DMAC7.html)
DE (2) DE602005017285D1 (cg-RX-API-DMAC7.html)
DK (2) DK1781802T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP077354A (cg-RX-API-DMAC7.html)
EG (1) EG26922A (cg-RX-API-DMAC7.html)
ES (2) ES2335518T3 (cg-RX-API-DMAC7.html)
GT (2) GT200500233A (cg-RX-API-DMAC7.html)
HN (1) HN2005000485A (cg-RX-API-DMAC7.html)
HR (2) HRP20100011T1 (cg-RX-API-DMAC7.html)
IL (1) IL181588A (cg-RX-API-DMAC7.html)
MX (1) MX2007002381A (cg-RX-API-DMAC7.html)
MY (1) MY137803A (cg-RX-API-DMAC7.html)
NO (1) NO344785B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ579208A (cg-RX-API-DMAC7.html)
PE (2) PE20100448A1 (cg-RX-API-DMAC7.html)
PL (2) PL1992697T3 (cg-RX-API-DMAC7.html)
PT (2) PT1992697E (cg-RX-API-DMAC7.html)
RS (2) RS51255B (cg-RX-API-DMAC7.html)
RU (1) RU2458988C2 (cg-RX-API-DMAC7.html)
SI (2) SI1781802T1 (cg-RX-API-DMAC7.html)
SV (1) SV2006002211A (cg-RX-API-DMAC7.html)
TW (1) TWI364458B (cg-RX-API-DMAC7.html)
UA (1) UA89383C2 (cg-RX-API-DMAC7.html)
WO (1) WO2006026447A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200701672B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101439195B1 (ko) 2013-04-18 2014-09-12 동아대학교 산학협력단 에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
AR058140A1 (es) * 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
DK2041270T3 (da) * 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
MX2009004519A (es) * 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
MX2009004974A (es) * 2006-11-08 2009-05-20 Wyeth Corp Medios diseñado racionalmente para cultivo celular.
CA2679941C (en) * 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
WO2008136398A1 (ja) 2007-04-26 2008-11-13 Chugai Seiyaku Kabushiki Kaisha 高濃度アミノ酸含有培地を用いた細胞の培養方法
AU2009236187B2 (en) * 2008-04-17 2012-08-02 Wyeth Llc Methods for enhanced production of bone morphogenetic proteins
CN102007207B (zh) * 2008-04-18 2012-05-30 上海抗体药物国家工程研究中心有限公司 一种浓缩培养液及其使用方法
EP2331700A2 (en) 2008-08-08 2011-06-15 Biogen Idec MA Inc. Nutrient monitoring and feedback control for increased bioproduct production
MX355650B (es) 2009-08-11 2018-04-26 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
EP2507267B1 (en) * 2009-12-02 2016-09-14 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
CN102858953B (zh) 2010-04-26 2015-09-09 诺瓦提斯公司 改进的细胞培养基
LT2563906T (lt) 2010-04-26 2018-02-26 Novartis Ag Cho ląstelių kultivavimo būdas
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
JP2014503495A (ja) * 2010-11-15 2014-02-13 バイオジェン アイデック インコーポレイテッド 過負荷結合および溶出クロマトグラフィによる選択生成物アイソフォームの富化および濃縮
US9631216B2 (en) 2011-04-29 2017-04-25 Biocon Research Limited Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
AU2012326170B2 (en) 2011-10-18 2016-12-22 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
EP2768944B2 (en) * 2011-10-21 2023-11-22 Pfizer Inc. Addition of iron to improve cell culture
JP2015509714A (ja) * 2012-02-22 2015-04-02 エヌヴィーアイピー プロプライエタリー リミテッド 腫瘍壊死因子レセプター融合タンパク質及び前記タンパク質を使用する方法
WO2014011629A1 (en) 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Stable aqueous formulations of etanercept
KR102250937B1 (ko) 2012-09-11 2021-05-12 코히러스 바이오사이언시즈, 인코포레이티드 고순도 및 탁월한 수율의 정확하게 폴딩된 에타너셉트
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
SG10201802023RA (en) 2013-03-26 2018-05-30 Coherus Biosciences Inc Protein production method
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
PL3812453T3 (pl) * 2013-10-11 2026-07-13 Regeneron Pharmaceuticals, Inc. Hodowla komórkowa zoptymalizowana metabolicznie
US10047141B2 (en) 2014-01-30 2018-08-14 Coherus Biosciences, Inc. Method of manufacturing a protein by perfusion in media with a low amino acid concentration
NZ722391A (en) 2014-02-04 2022-12-23 Biogen Ma Inc Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
CA2969225C (en) 2014-12-01 2023-08-22 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
CN105777897A (zh) * 2015-03-20 2016-07-20 广东东阳光药业有限公司 一种cho细胞收获液的前处理方法
US11505784B2 (en) * 2015-04-01 2022-11-22 Boehringer Ingelheim International Gmbh Cell culture medium
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
CN110484487A (zh) * 2019-08-21 2019-11-22 安徽欣乐生物技术有限公司 一种适用于cho细胞培养用无蛋白培养基及其培养方法
EP4267717A1 (en) 2020-12-22 2023-11-01 Amgen Inc. Cell culture method
CN115073607A (zh) * 2021-03-12 2022-09-20 上海康岱生物医药技术股份有限公司 Tnfr2与baff受体的融合蛋白
CN114480492B (zh) * 2022-01-28 2023-04-21 景泽生物医药(合肥)股份有限公司 一种重组人抗体融合蛋白的制备方法
CN119510778A (zh) * 2024-12-31 2025-02-25 北京同立海源生物科技有限公司 一种高稳定性的pdgf-bb活性检测方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447851A (en) * 1992-04-02 1995-09-05 Board Of Regents, The University Of Texas System DNA encoding a chimeric polypeptide comprising the extracellular domain of TNF receptor fused to IgG, vectors, and host cells
WO1996039488A1 (en) * 1995-06-06 1996-12-12 Genentech, Inc. Process for controlling sialylation of proteins produced by mammalian cell culture
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) * 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1990003430A1 (en) * 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
ES2118066T3 (es) * 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5156964A (en) * 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
GB9118664D0 (en) * 1991-08-30 1991-10-16 Celltech Ltd Cell culture
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性IgE受容体モノクローナル抗体に係るアミノ酸配列をコードするDNA断片
US6310185B1 (en) 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
US5856179A (en) * 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6656466B1 (en) * 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
EP1150688A4 (en) 1998-10-19 2004-06-16 Yeda Res & Dev TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS BY NEGATIVE REGULATION OF THE AUTO-IMMUNE RESPONSE TO AUTOANTIGENS
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
ATE409047T1 (de) 2001-04-30 2008-10-15 Lilly Co Eli Humanisierte antikörper
AU2002258808A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
US20030087372A1 (en) 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
BR0307907A2 (pt) 2002-02-21 2011-07-05 Wyeth Corp gasp1: proteìna contendo domìnio de folistatina
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447851A (en) * 1992-04-02 1995-09-05 Board Of Regents, The University Of Texas System DNA encoding a chimeric polypeptide comprising the extracellular domain of TNF receptor fused to IgG, vectors, and host cells
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1996039488A1 (en) * 1995-06-06 1996-12-12 Genentech, Inc. Process for controlling sialylation of proteins produced by mammalian cell culture
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101439195B1 (ko) 2013-04-18 2014-09-12 동아대학교 산학협력단 에셰리키아 콜리 a-53 균주를 이용하여 섬유소 분해효소의 생산성을 향상시키는 공정

Also Published As

Publication number Publication date
KR20070069140A (ko) 2007-07-02
ES2341390T3 (es) 2010-06-18
EP1781802B1 (en) 2009-10-21
NZ579208A (en) 2012-01-12
AR050537A1 (es) 2006-11-01
BRPI0514694A (pt) 2008-06-17
US20060121569A1 (en) 2006-06-08
PL1781802T3 (pl) 2010-03-31
EG26922A (en) 2014-12-25
CY1109721T1 (el) 2014-08-13
BRPI0514694B8 (pt) 2021-05-25
HRP20100271T1 (hr) 2010-06-30
PE20060815A1 (es) 2006-09-14
AU2005280036A1 (en) 2006-03-09
GT200500234A (es) 2006-10-10
RS51072B (sr) 2010-10-31
IL181588A0 (en) 2007-07-04
BRPI0514694B1 (pt) 2019-04-24
JP2016056214A (ja) 2016-04-21
ATE446376T1 (de) 2009-11-15
PL1992697T3 (pl) 2010-08-31
HK1121497A1 (en) 2009-04-24
DE602005020076D1 (de) 2010-04-29
GT200500233A (es) 2006-03-09
RU2458988C2 (ru) 2012-08-20
IL181588A (en) 2010-12-30
ECSP077354A (es) 2007-05-30
JP2012095672A (ja) 2012-05-24
WO2006026447A3 (en) 2006-04-20
HN2005000485A (es) 2009-06-09
PT1781802E (pt) 2010-01-04
AU2005280036B2 (en) 2011-11-03
ZA200701672B (en) 2012-04-24
WO2006026447A2 (en) 2006-03-09
NO344785B1 (no) 2020-04-27
CN101061231A (zh) 2007-10-24
PE20100448A1 (es) 2010-06-22
CL2017000577A1 (es) 2017-12-01
TWI364458B (en) 2012-05-21
JP2008511330A (ja) 2008-04-17
WO2006026447A9 (en) 2006-06-01
CR20120560A (es) 2012-12-04
DK1781802T3 (da) 2010-01-25
CY1110092T1 (el) 2015-01-14
RS51255B (sr) 2010-12-31
SI1992697T1 (sl) 2010-07-30
ES2335518T3 (es) 2010-03-29
US7300773B2 (en) 2007-11-27
HRP20100011T1 (hr) 2010-02-28
EP1992697B1 (en) 2010-03-17
MX2007002381A (es) 2007-06-15
AR088824A2 (es) 2014-07-10
HK1099941A1 (en) 2007-08-31
JP5921910B2 (ja) 2016-05-24
CN101061231B (zh) 2012-09-26
CN102876761A (zh) 2013-01-16
NO20071570L (no) 2007-05-23
PT1992697E (pt) 2010-04-21
MY137803A (en) 2009-03-31
SI1781802T1 (sl) 2010-01-29
TW200619388A (en) 2006-06-16
UA89383C2 (ru) 2010-01-25
SV2006002211A (es) 2006-10-04
ATE461285T1 (de) 2010-04-15
EP1781802A2 (en) 2007-05-09
EP1992697A1 (en) 2008-11-19
RU2007108717A (ru) 2008-10-10
CR8998A (es) 2007-11-23
DK1992697T3 (da) 2010-05-17
DE602005017285D1 (cg-RX-API-DMAC7.html) 2009-12-03
CA2578138C (en) 2010-10-05
CA2578138A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
KR100998857B1 (ko) 항-아밀로이드 베타 항체의 생산
KR101158447B1 (ko) 폴리펩타이드의 생산
KR20070069140A (ko) TNFR-Ig 융합 단백질의 제조
HK1180013B (en) Production of polypeptides
HK1181073A (en) Production of tnfr-ig fusion protein
HK1180013A (en) Production of polypeptides
AU2012200353A1 (en) PRODUCTION OF a-ABeta

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

A302 Request for accelerated examination
PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20130927

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20140929

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20160929

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20180928

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20190924

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 14

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 15

PC1801 Expiration of term

St.27 status event code: N-4-6-H10-H14-oth-PC1801

Not in force date: 20250827

Ip right cessation event data comment text: Termination Category : EXPIRATION_OF_DURATION